Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome.

  title={Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome.},
  author={Maarten J. Titulaer and Paul W. Wirtz and Luuk N. A. Willems and Klaas W. van Kralingen and P A Smitt and Jan Verschuuren},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={26 26},
  • M. TitulaerP. Wirtz J. Verschuuren
  • Published 10 September 2008
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE A small-cell lung carcinoma (SCLC) is found in 50% of patients with Lambert-Eaton myasthenic syndrome (LEMS). We evaluated screening to optimize screening strategy for SCLC. It is important to detect these tumors early in newly diagnosed patients with LEMS to offer optimal patient treatment. PATIENTS AND METHODS A large nationwide cohort study of consecutive patients in the Netherlands, seen between 1990 and 2007, were screened for the presence of a tumor using chest x-ray, computed… 

Figures and Tables from this paper

Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers

Computed tomography screening is ineffective for small cell lung cancer and efforts to reduce mortality of SCLC should instead focus on prevention through tobacco reduction programs, as well as the development of improved treatment options.

The clinical DELTA-P score accurately predicts small cell lung cancer in the Lambert-Eaton myasthenic syndrome

A simple clinical DELTA-P score discriminated LEMS patients with and without SCLC with high accuracy early in the course of LEMS, and was derived based on multivariate logistic regression.

18F-FDG PET-CT in the evaluation of paraneoplastic syndromes: experience at a regional oncology centre

PET-CT is a highly sensitive and specific imaging technique in the evaluation of PNS and adds confidence to clinical likelihood and is estimated to have 100% sensitivity, 82% specificity, 42% positive predictive value and 100% negative predictive value.

Benefit from thoracic radiotherapy in patients with extensive-disease small-cell lung cancer with elevated lactate dehydrogenase

The use of TRT improves the survival of patients with ED-SCLC and future studies should use the LDH level for categorizing patients for treatment, which is associated with a large tumor burden in extensive-disease small-cell lung cancer.

Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort

The DELTA-P cancer prediction score, calculated at the time of LEMS diagnosis, is an effective tool for cancer screening in an independent, prospective study setting.

Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS.

The simple clinical DELTA-P score discriminated patients with LEMS with and without SCLC with high accuracy early in the course of LEMS, and was validated in a similar cohort of 112 British patients.

Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients

FDG-PET/CT has in patients with suspected PNS an impressively high negative predictive value and may be of value in ruling out PNS, the more so the more the number of false positives can be minimized or used in differential diagnosis.

Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome

Improved SCLC tumor survival seen in patients with LEMS and SclC may not be due solely to lead time bias, given that survival advantage remains after allowing for other prognostic factors and that the same degree of survival advantage is not seen in Patients with paraneoplastic neurologic syndromes other than LEMS presenting before SCLS diagnosis.

Lambert-Eaton Myasthenic Syndrome Secondary to Nivolumab and Ipilimumab in a Patient with Small-Cell Lung Cancer

A 59-year-old male with a confirmed diagnosis of small-cell lung cancer was diagnosed with hypothyroidism, primary adrenal insufficiency, and Lambert-Eaton Myasthenic Syndrome (LEMS) and felt that LEMS was an immunotherapy-related adverse effect rather being a paraneoplastic syndrome.

SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival.

SOX antibodies have diagnostic value in discriminating SCLC-LEMS from nontumor LEMS, but have no relation to survival in patients with SclC.



Survival of patients with stage I lung cancer detected on CT screening.

BACKGROUND The outcome among patients with clinical stage I cancer that is detected on annual screening using spiral computed tomography (CT) is unknown. METHODS In a large collaborative study, we

HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert–Eaton myasthenic syndrome

FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.

FDG-PET should be reserved, at the moment, for patients with well-defined PNS antibodies when conventional imaging fails to identify a tumour or when lesions are difficult to biopsy.

Computed tomography screening and lung cancer outcomes.

Screening for lung cancer with low-dose CT may increase the rate of lung cancer diagnosis and treatment, but may not meaningfully reduce the risk of advanced lung cancer or death from lung cancer.

Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

The analysis indicates that the incidence of SCLC is decreasing in the United States, and only modest improvements have been seen in survival over the last 30 years.

Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute.

The results of the LSS demonstrated convincingly the feasibility of an RCT of LDCT scanning in the United States.

The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands

The Lambert-Eaton myasthenic syndrome (LEMS) is presumed to be rare, but epidemiologic studies in large circumscribed populations have not been performed, and the prevalence and incidence of LEMS and the frequency of underlying SCLC in the Netherlands is established.

Lambert–Eaton Myasthenic Syndrome

Data support a role for the LEMS‐related immune response in suppressing the tumor activity and compare the clinical and laboratory characteristics of tumor and nontumor related LEMS patients.